HCW Biologics HCWB 深 沪
等待开盘 12-19 09:30:00 美东时间
1.63
-0.105
-6.05%
华盛通- 最 高1.79
- 今 开1.79
- 成交量 2.26万股
- 最 低 1.55
- 昨 收 1.735
- 总市值 350.71万
- 52周最高 41.20
- 市盈率 静 --
- 换手率 1.05%
- 52周最低 1.52
- 委 比 -62.50%
- 总股本 215.16万
- 历史最高 311.00
- 量 比 0.31
- 振 幅 13.83%
- 历史最低 1.55
- 每 手 1
- 风险率 4.98%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多HCW Biologics Begins Phase 1 Trial for HCW9302
The latest update is out from HCW Biologics ( ($HCWB) ). On November 18, 2025, ...
11-18 20:59
HCW Biologics Q3 EPS $(2.02) Misses $1.58 Estimate, Sales $15.606M Beat $7.000M Estimate
HCW Biologics (NASDAQ:HCWB) reported quarterly losses of $(2.02) per share which missed the analyst consensus estimate of $1.58 by 227.85 percent. This is a 49.5 percent increase over losses of $(4.00) per share from the
11-15 05:47
HCW Biologics Reports Third Quarter 2025 Business Highlights and Financial Results
HCW Biologics reported its third-quarter 2025 financial results and business highlights, including the planned Phase 1 clinical trial for HCW9302, a novel immunotherapy targeting autoimmune diseases, and the launch of a search for a commercial partner for its T-cell engager compounds. The company also highlighted the IND-enabling studies for HCW9302 and showcased data for its second-generation TCE and immune checkpoint inhibitor programs. Despite...
11-14 21:44
HCW Biologics Unveils New Cancer Therapy Designed to 'Reawaken' Immune Cells to Fight Solid Tumors
HCW Biologics Inc. (the "Company" or "HCW Biologics"), (NASDAQ:HCWB), a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen healthspan by disrupting
11-07 20:09
HCW Biologics Granted Nasdaq Compliance Extension
HCW Biologics ( ($HCWB) ) just unveiled an announcement. On August 19, 2025, HC...
10-16 21:30
HCW Biologics to Participate in the 2025 Maxim Growth Summit
HCW Biologics Inc. to Participate in 2025 Maxim Growth Summit HCW Biologics Inc. (NASDAQ: HCWB), a U.S.-based clinical-stage biopharmaceutical company, will participate in the 2025 Maxim Growth Summit from October 22-23 at The Hard Rock Hotel NYC. Dr. Hing C. Wong, the Company’s Founder and CEO, will meet with institutional investors and senior Maxim analysts. The summit will feature keynote speakers Larry Kudlow and Christopher Ruddy, along w...
10-16 13:25
HCW Biologics’ Scientists to Present Three Posters During the 40th Annual Meeting of the Society for Immunotherapy of Cancer
HCW Biologics Inc. will present three posters at the upcoming Society for Immunotherapy of Cancer Annual Meeting showcasing its lead drug candidates developed using the novel TRBC platform technology. The TRBC platform enables the creation of three classes of immunotherapeutics: multi-functional immune cell stimulators, second-generation immune checkpoint inhibitors, and multi-specific targeting fusions. Poster presentations will occur on Novembe...
10-16 13:15
HCW Biologics Inc. (NASDAQ: HCWB) Participates in Virtual Investor “What This Means” Segment About its Proprietary T-Cell Engager Program
HCW Biologics Inc. announced advancements in its second-generation T-Cell Engager (TCE) program, addressing challenges of the first generation such as manufacturing complexity and safety concerns. The program demonstrates improved manufacturability, safety profile, and efficacy against solid tumors, positioning the company among innovative biotech firms. Dr. Peter Rhode discussed these developments in a Virtual Investor segment, highlighting the ...
09-30 12:45
HCW Biologics, a Shareholder of Wugen, Congratulates Wugen on Its Recent Successful Equity Financing
HCW Biologics congratulates Wugen on securing a $115 million equity financing led by Fidelity, with HCW holding a minority stake in Wugen from their 2020 license agreement. The Company has generated $16.2 million in revenues through this partnership. HCW, focused on immunotherapies for inflammation-related diseases, highlights Wugen's advancements in CAR-T cell therapies. Wugen, based in St. Louis, is pioneering off-the-shelf cell therapies for h...
09-18 13:15
HCW Biologics Designates One of Its Proprietary TRBC-Pembrolizumab-Based Immune Checkpoint Inhibitors as its Franchise Immunotherapeutic for Internal Clinical Development
HCW Biologics announced positive preclinical data for its lead product candidate, HCW11-040, a multi-functional fusion protein combining pembrolizumab (Keytruda), IL-7, IL-15, and TGF-β traps. The molecule demonstrated superior immune-cell activation, tumor infiltration, and anti-tumor effects compared to pembrolizumab alone, while avoiding cytokine storm risks. HCW Biologics plans to advance HCW11-040 into late IND-enabling studies for potential...
09-16 12:00
